Experimental Drug Dordaviprone Shows Promise Against Rare, Incurable Brain Tumor in Study
ONC201 (dordaviprone) displayed “well tolerated and durable and clinically meaningful efficacy in Histone 3 (H3) K27M mutant-diffuse midline glioma DMG.”
An experimental drug option, ONC201 (dordaviprone) could act as a new treatment for some patients with a rare incurable brain tumor, Histone 3 (H3) K27M mutant-diffuse midline glioma DMG.
In a study recently published in the Journal of Clinical Oncology, dordaviprone displayed “well tolerated and durable and clinically meaningful efficacy in [H3 K27M-DMG.]”
The (H3) K27M mutation is common DMG leads to a poor median overall survival (OS) of around 1 year, with prognosis varying based on genotype and age at diagnosis. These gliomas, primarily found in midline brain structures, often cannot be surgically removed.
Researchers across numerous health systems in the U.S examined the use of dordaviprone in DMG as the brain tumor has a dismal prognosis with no established effective therapy beyond radiation.
There were 50 patients (pediatric: 4; adult: 46) with recurrent H3 K27M–mutant DMG who received dordaviprone monotherapy in the clinical trial.
Eligible patients had a measurable disease and performance score (PS) more than 60 and were 90 days from radiation, with other brain tumors excluded.
The study assessed response rates, duration (DOR) and time to response (TTR) using Response Assessment in Neuro-Oncology (RANO) criteria in recurrent H3 K27M–mutant DMG patients receiving the monotherapy.
Results showed a 20.0% ORR (RANO- high-grade glioma (HGG)) with a median TTR of 8.3 months and a median DOR of 11.2 months.
The combined ORR by RANO-HGG or low-grade glioma (LGG) criteria was 30.0%. Corticosteroid dose reduction (more than 50%) occurred in 46.7%, and PS improvement in 20.6% of patients.
Grade 3 treatment-related adverse events were 20.0%, with fatigue being the most common (10%); no grade 4 events, deaths, or discontinuations occurred.
With limited effective therapies for H3 K27M–mutant DMG, the poor prognosis needs further research on dordaviprone’s efficacy.
A phase II study for newly diagnosed cases is ongoing.
The 2021 WHO disease definition suggests further research of dordaviprone in H3 K27me3 loss patients, regardless of H3 K27M mutation presence.Bottom of Form
Attacking PRPS Enzymes Offers Hope for Treating Fast-Growing Myc-Driven Lymphomas
June 10th 2025Researchers found that altering key enzymes involved in redox balance could disrupt the metabolism of Myc-driven lymphomas, which offers a potential new strategy to treat aggressive cancers.
Read More
The First Financial Toxicity Tumor Board Reports Success in Individual Patient Savings
May 14th 2025Financial toxicity can affect patient outcomes and quality of life. For example, a patient may forgo treatment or medications to save money, or they may incur high medical debt or go into bankruptcy to pay for medical care.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Since then, six additional CAR-T cell therapies have been introduced to the market. Four of the seven are approved for B-cell lymphomas.
Read More
